Analysts’ Weekly Ratings Updates for SAGE Therapeutics (SAGE)

Several analysts have recently updated their ratings and price targets for SAGE Therapeutics (NASDAQ: SAGE):

  • 11/20/2018 – SAGE Therapeutics was given a new $170.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/16/2018 – SAGE Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 11/12/2018 – SAGE Therapeutics is now covered by analysts at Leerink Swann. They set an “underperform” rating and a $80.00 price target on the stock.
  • 11/6/2018 – SAGE Therapeutics was given a new $205.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 11/5/2018 – SAGE Therapeutics had its price target raised by analysts at Royal Bank of Canada from $259.00 to $261.00. They now have an “outperform” rating on the stock.
  • 11/4/2018 – SAGE Therapeutics was given a new $170.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/2/2018 – SAGE Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 11/1/2018 – SAGE Therapeutics was given a new $220.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/1/2018 – SAGE Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $207.00 price target on the stock.
  • 10/31/2018 – SAGE Therapeutics was given a new $235.00 price target on by analysts at LADENBURG THALM/SH SH. They now have a “buy” rating on the stock.
  • 10/29/2018 – SAGE Therapeutics was given a new $170.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/17/2018 – SAGE Therapeutics is now covered by analysts at Oppenheimer Holdings Inc.. They set a “buy” rating and a $170.00 price target on the stock.
  • 10/11/2018 – SAGE Therapeutics had its price target raised by analysts at Morgan Stanley from $228.00 to $230.00. They now have an “overweight” rating on the stock.
  • 10/10/2018 – SAGE Therapeutics is now covered by analysts at Oppenheimer Holdings Inc.. They set a “buy” rating and a $170.00 price target on the stock.

SAGE stock traded up $0.92 during trading on Monday, reaching $112.70. The stock had a trading volume of 240,988 shares, compared to its average volume of 491,626. SAGE Therapeutics Inc has a 1-year low of $88.03 and a 1-year high of $195.97. The firm has a market capitalization of $5.24 billion, a P/E ratio of -15.90 and a beta of 2.76.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) EPS for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same period in the previous year, the business posted ($1.97) EPS. Research analysts predict that SAGE Therapeutics Inc will post -7.58 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of SAGE. FMR LLC increased its position in shares of SAGE Therapeutics by 0.3% in the 3rd quarter. FMR LLC now owns 6,999,644 shares of the biopharmaceutical company’s stock worth $988,700,000 after purchasing an additional 22,266 shares during the last quarter. Vanguard Group Inc. increased its position in shares of SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the last quarter. BlackRock Inc. increased its position in shares of SAGE Therapeutics by 0.9% in the 3rd quarter. BlackRock Inc. now owns 2,816,410 shares of the biopharmaceutical company’s stock worth $397,818,000 after purchasing an additional 23,862 shares during the last quarter. OppenheimerFunds Inc. increased its position in shares of SAGE Therapeutics by 2.2% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock worth $250,162,000 after purchasing an additional 34,389 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of SAGE Therapeutics by 7.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock worth $244,898,000 after purchasing an additional 110,134 shares during the last quarter.

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Story: Trading Strategy Methods for Individual Investors

Receive News & Ratings for SAGE Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply